文献速递妇科产科

在晚期子宫内膜癌中,多柔比星和顺铂基础上加用紫杉醇联合容积导向放疗未改善总生存或无复发生存:一项随机III期NRG/妇科肿瘤组研究

The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
PubMed 文献 · Gynecol Oncol · 2019-04-30

本研究为前瞻性随机III期GOG试验,在晚期子宫内膜癌患者手术减瘤和容积导向放疗后比较顺铂+多柔比星(CD)联合或不联合紫杉醇(P)的疗效。长期随访显示两组总生存和无复发生存无显著差异,亚组分析提示CDP联合EFRT有改善趋势,且需持续癌症筛查。

要点

  • 在CD方案基础上加用紫杉醇未显著降低复发或死亡风险(p=0.14,单侧)。
  • 探索性分析仅EFRT和EFRT&GRD状态亚组显示治疗效应显著不同(p=0.027和p=0.017)。
  • 第二原发恶性肿瘤在CD组为17/253(6.4%),CDP组为19/263(7.0%)。

核心结论

  • 两组治疗臂间未发现显著差异。
  • 初始和当前报告的亚组分析均显示CDP联合EFRT治疗的患者无复发生存和总生存有改善趋势。
  • 长期结局分析还确定需要为入组试验的患者提供持续癌症筛查。

研究设计与样本

  • 前瞻性随机GOG试验,比较在容积导向放疗和手术后CD(50 mg/m2/45 mg/m2)联合或不联合P(160 mg/m2)治疗晚期子宫内膜癌。
  • 采用Kaplan-Meier分析、对数秩检验和按分期分层的Cox比例风险模型评估生存结局。
  • 不良事件无论归因均进行分级。

主要发现

  • 自初次发表以来发生60例死亡,311例患者存活,其中290例(93.8%)无复发。
  • 按分期分层,CDP方案未显著降低复发或死亡风险(p=0.14,单侧)。
  • 总生存的探索性分析和亚组同质性检验仅发现EFRT和EFRT&GRD状态的治疗效应显著不同(p=0.027和p=0.017)。
  • 第二原发恶性肿瘤在CD组为17/253(6.4%),CDP组为19/263(7.0%);最常见为乳腺癌(2.4%)和结肠癌(1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if the addition of paclitaxel (P) to cisplatin and doxorubicin (CD) following surgical debulking and volume-directed radiation therapy improved long-term, recurrence-free survival (RFS) and overall survival (OS) in patients with advanced-stage endometrial cancer (EC). METHODS: Prospective, randomized GOG trial comparing (CD) (50 mg/m2)/(45 mg/m2) +/- (P) (160 mg/m2) following volume-directed radiation and surgery in advanced EC. A Kaplan-Meier (KM) analysis characterized the relationship between treatment arms and the OS outcome, a log-rank test assessed the independence of treatment with the OS outcome, and the treatment effect on estimated OS was determined using a Cox proportional hazards (PH) model stratified by stage. The PH assumption was assessed using a test of interaction between treatment variable and the natural logarithm of survival time. Adverse events, regardless of attribution, were graded. RESULTS: Since initial publication, 60 deaths occurred, leaving 311 patients alive with 290 (93.8%) recurrence- free. There was no significant decrease in the risk of recurrence or death associated with the CDP treatment regimen stratified for stage (p = 0.14, one-tail). The exploratory analysis for OS and the corresponding homogeneity tests for different effects across subgroups revealed only EFRT and EFRT & GRD status to have significantly different treatment effects (p = 0.027 and p = 0.017, respectively). Second primary malignancies were identified in 17/253 (6.4%) and 19/263 (7.0%) of patients treated with CD and CDP respectively. Breast (2.4%) followed by colon (1%) were the two cancers most frequently diagnosed in this setting. CONCLUSION: No significant difference between treatment arms was identified. Subgroup analysis both in the initial and current reports demonstrated a trend towards improved RFS and OS in patients treated with CDP and EFRT. This long-term analysis of outcomes also identified the necessity of providing on-going cancer screening to patients enrolled in trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Spirtos NM, Enserro D, Homesley HD, et al. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2019. PMID: 31053405. doi:10.1016/j.ygyno.2019.03.240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。